KR20140068936A - 망막 변성 질환의 치료방법 - Google Patents

망막 변성 질환의 치료방법 Download PDF

Info

Publication number
KR20140068936A
KR20140068936A KR1020147006060A KR20147006060A KR20140068936A KR 20140068936 A KR20140068936 A KR 20140068936A KR 1020147006060 A KR1020147006060 A KR 1020147006060A KR 20147006060 A KR20147006060 A KR 20147006060A KR 20140068936 A KR20140068936 A KR 20140068936A
Authority
KR
South Korea
Prior art keywords
cells
cell
wnt
retinal
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147006060A
Other languages
English (en)
Korean (ko)
Inventor
마리아 피아 코스마
다니엘라 상게스
Original Assignee
마리아 피아 코스마
다니엘라 상게스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마리아 피아 코스마, 다니엘라 상게스 filed Critical 마리아 피아 코스마
Publication of KR20140068936A publication Critical patent/KR20140068936A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147006060A 2011-08-05 2012-08-06 망막 변성 질환의 치료방법 Withdrawn KR20140068936A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases
EP11176713.3 2011-08-05
PCT/EP2012/065327 WO2013020945A1 (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Publications (1)

Publication Number Publication Date
KR20140068936A true KR20140068936A (ko) 2014-06-09

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147006060A Withdrawn KR20140068936A (ko) 2011-08-05 2012-08-06 망막 변성 질환의 치료방법

Country Status (15)

Country Link
US (1) US20140199277A1 (https=)
EP (2) EP2554662A1 (https=)
JP (1) JP2014527407A (https=)
KR (1) KR20140068936A (https=)
CN (1) CN104011203A (https=)
AR (1) AR087471A1 (https=)
AU (1) AU2012293681A1 (https=)
BR (1) BR112014002718A8 (https=)
CA (1) CA2844106A1 (https=)
CO (1) CO7081142A2 (https=)
IL (1) IL230830A0 (https=)
MX (1) MX2014001475A (https=)
RU (1) RU2014108478A (https=)
SG (1) SG2014008080A (https=)
WO (1) WO2013020945A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194256A1 (ko) * 2020-03-25 2021-09-30 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889441A (zh) 2011-09-29 2014-06-25 伊丽莎白女王在都柏林附近神圣不可分割的三一学院教务长、研究员、学者及董事会其他成员 用于治疗退行性视网膜病况的组合物和方法
AU2014378349B2 (en) 2014-01-17 2021-06-03 Riken Method for manufacturing ciliary margin stem cells
BR112017005235B1 (pt) * 2014-09-16 2023-10-31 Genzyme Corporation Vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
WO2018034945A1 (en) * 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
JP2020518915A (ja) 2017-04-27 2020-06-25 パスハラキス スタブロスＰＡＳＣＨＡＬＡＫＩＳ， Ｓｔａｖｒｏｓ 自動眼底画像分析用のシステムおよび方法
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
WO2018232258A1 (en) * 2017-06-15 2018-12-20 University Of North Texas Health Science Center Reprogramming fibroblasts to retinal cells
CN117379543A (zh) * 2017-08-20 2024-01-12 加州大学董事会 治疗青光眼的Wnt5a的调节
WO2019195717A1 (en) * 2018-04-06 2019-10-10 Icahn School Of Medicine At Mount Sinai Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells
WO2020190848A1 (en) * 2019-03-15 2020-09-24 The Schepens Eye Research Institute, Inc. Isolation, enrichment and expansion of cone progenitor cells and uses thereof
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜
US12558336B2 (en) 2019-09-25 2026-02-24 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
EP1237880B1 (en) 1999-12-17 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
CN100335479C (zh) 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
CA2446756C (en) 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
EP1472245A2 (en) 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
US20050203059A1 (en) 2002-03-01 2005-09-15 Harrison Stephen D. Methods and compositions for treatment of ischemia
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
AU2003268184A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
JP2006506383A (ja) 2002-10-21 2006-02-23 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のインヒビター
BRPI0409861A (pt) * 2003-05-02 2006-05-16 Scripps Research Inst células- tronco hematopoiéticas e sua utilização em métodos de tratamento de doenças oculares neovasculares
JP2007502300A (ja) 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
JP2008512376A (ja) * 2004-09-03 2008-04-24 ザ・スクリプス・リサーチ・インステイチユート 単離された系統陰性造血幹細胞及びこれを用いた治療方法
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
AU2006216473B2 (en) 2005-02-24 2012-07-26 The Scripps Research Institute Method for the treatment of retinopathy of prematurity and related retinopathic diseases
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
CA2613889A1 (en) * 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
NZ582616A (en) * 2007-06-15 2012-07-27 Garnet Biotherapeutics Inc Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
GB0816577D0 (en) * 2008-09-11 2008-10-15 Axordia Ltd Growth factor
KR101268741B1 (ko) * 2009-10-06 2013-06-04 김지연 줄기세포를 망막세포로 분화시키는 방법

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194256A1 (ko) * 2020-03-25 2021-09-30 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포

Also Published As

Publication number Publication date
AU2012293681A1 (en) 2014-03-06
RU2014108478A (ru) 2015-09-10
WO2013020945A1 (en) 2013-02-14
JP2014527407A (ja) 2014-10-16
MX2014001475A (es) 2014-07-22
US20140199277A1 (en) 2014-07-17
EP2554662A1 (en) 2013-02-06
AR087471A1 (es) 2014-03-26
CN104011203A (zh) 2014-08-27
WO2013020945A9 (en) 2013-04-04
IL230830A0 (en) 2014-03-31
CA2844106A1 (en) 2013-02-14
SG2014008080A (en) 2014-03-28
NZ621345A (en) 2015-09-25
CO7081142A2 (es) 2014-10-10
EP2739723A1 (en) 2014-06-11
BR112014002718A8 (pt) 2017-06-20
BR112014002718A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
KR20140068936A (ko) 망막 변성 질환의 치료방법
JP7162221B2 (ja) 網膜組織を含む細胞凝集体及びその製造方法
Xiao et al. Neurotrophic factor GDNF promotes survival of salivary stem cells
JP6792844B6 (ja) 網膜色素上皮細胞の製造方法
Huang et al. Stem cell-based therapeutic applications in retinal degenerative diseases
Sarkar et al. CD11b+ GR1+ myeloid cells secrete NGF and promote trigeminal ganglion neurite growth: implications for corneal nerve regeneration
Congdon et al. Activation of Wnt signaling in hematopoietic regeneration
JPWO2018164240A1 (ja) 網膜色素上皮細胞の製造方法
Huang et al. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart
JP2025028314A (ja) 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬
TW201908478A (zh) 調節米勒神經膠質細胞之方法
Ahamad et al. Bone marrow stem cells, aging, and age-related diseases
CN120112629A (zh) T细胞产生方法
Mussar et al. Macrophage/epithelium cross-talk regulates cell cycle progression and migration in pancreatic progenitors
KR20170093178A (ko) 전구 세포를 사용한 안구 질환의 치료
Tsupykov et al. Long‐term fate of grafted hippocampal neural progenitor cells following ischemic injury
TW202600814A (zh) γδT細胞組合物及使用方法
CA2628530C (en) Novel stem cells, nucleotide sequences and proteins therefrom
WO2015125941A1 (ja) 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法
Forte et al. Interfacing Sca‐1pos Mesenchymal Stem Cells with Biocompatible Scaffolds with Different Chemical Composition and Geometry
KR20180088713A (ko) 전구 세포를 사용한 망막 변성의 치료
NZ621345B2 (en) Methods of treatment of retinal degeneration diseases
EP3231434A1 (en) Method of treatment of parkinsonism
Ulrich Perspectives of stem cells: From tools for studying mechanisms of neuronal differentiation towards therapy
Morad Mesenchymal stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140305

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid